Researchers tested whether the GnRH antagonist degarelix was better at achieving and maintaining ovarian function suppression than the commonly used GnRH agonist triptorelin in premenopausal women with breast cancer.
More From BioPortfolio on "Can a Prostate Cancer Drug Improve OFS in Premenopausal Breast Cancer Patients?"